 |
 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about E.E.S.-200.
No reviews have yet been submitted. Be the first to review this drug.
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa CHICAGO, April 23, 2013 /PRNewswire/...
WAYNE, N.J., April 16, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III...
Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and...
Looking for answers? Ask a question or go join the E.E.S.-200 support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Apr 24th, 2013), Cerner Multum™ (updated Apr 19th, 2013), Wolters Kluwer™ (updated Apr 30th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
